(IN BRIEF) Roche has announced new data at the Euretina Congress in Paris from its AVONELLE-X and SALWEEN studies of Vabysmo (faricimab), confirming the therapy’s strong long-term outcomes for patients with retinal diseases. The AVONELLE-X study, the largest long-term extension … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged AVONELLE-X, bispecific antibody, diabetic macular edema, DME, durability, Euretina Congress, extended dosing, faricimab, Levi Garraway, long-term efficacy, LUCERNE, nAMD, neovascular age-related macular degeneration, ophthalmology, PCV, polypoidal choroidal vasculopathy, retinal vein occlusion, Roche, RVO, SALWEEN, TENAYA, Vabysmo, vision loss
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?